Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $2.00 price objective on the stock. D. Boral Capital’s target price would suggest a potential upside of 276.15% from the stock’s previous close.

A number of other equities analysts also recently commented on the company. Benchmark cut their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Monday, September 15th. Chardan Capital initiated coverage on shares of Reviva Pharmaceuticals in a report on Monday, September 29th. They issued a “buy” rating and a $2.00 price target on the stock. Roth Capital reiterated a “buy” rating and set a $3.00 price objective (down from $7.00) on shares of Reviva Pharmaceuticals in a research note on Monday, August 18th. Citigroup reissued a “buy” rating on shares of Reviva Pharmaceuticals in a research report on Friday, August 15th. Finally, Maxim Group reduced their target price on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Reviva Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $3.86.

Reviva Pharmaceuticals Stock Up 10.1%

Shares of RVPH opened at $0.53 on Wednesday. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28. The company’s fifty day moving average is $0.51 and its two-hundred day moving average is $0.57. The firm has a market cap of $36.87 million, a PE ratio of -1.16 and a beta of -0.04.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. As a group, equities research analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC purchased a new stake in Reviva Pharmaceuticals during the 2nd quarter worth $1,026,000. 683 Capital Management LLC purchased a new position in Reviva Pharmaceuticals in the 2nd quarter valued at about $381,000. Persistent Asset Partners Ltd grew its stake in shares of Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after acquiring an additional 480,864 shares in the last quarter. Millennium Management LLC increased its position in shares of Reviva Pharmaceuticals by 15.0% during the third quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after acquiring an additional 223,178 shares during the last quarter. Finally, Private Advisor Group LLC acquired a new position in shares of Reviva Pharmaceuticals in the first quarter worth about $191,000. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.